Outcome of palliative self-expanding metal stent placement in malignant colorectal obstruction according to stent type and manufacturer.
BACKGROUND
Self-expandable metallic stents (SEMS) of varying designs and materials have been developed to reduce complications, but few comparative data are available with regard to the type of stent and the stent manufacturer. We analyzed the success rates and complication rates, according to stent type (uncovered vs. covered stent) and individual stent manufacturer, in malignant colorectal obstruction.


METHODS
From November 2001 to August 2008, 103 patients were retrospectively included in this study: four types of uncovered stents in 73 patients and two types of covered stents in 30 patients. The SEMS was inserted into the obstructive site by using the through-the-scope method.


RESULTS
Technical and clinical success rates were not different between stent type or among stent manufacturers: 100 and 100% (p = ns) and 100 and 96.6% (p > 0.05), respectively, in uncovered and covered stents. Stent occlusion and migration rates were 12.3 and 3.3% (p = 0.274) and 13.7 and 16.7% (p = 0.761), respectively, in uncovered and covered stents, and 11.1, 5, and 9% (p = 0.761) and 25.9, 15, and 0% (p = 0.037) in Wallstent, Niti-S, and Bonastent uncovered stents, respectively.


CONCLUSIONS
The placement of SEMS is an effective and safe treatment for patients with malignant colorectal obstruction. Although minor differences in outcome were detected according to the type and the manufacturer of the stents, no statistically significant difference was observed, except in stent migration among the stent manufacturer.
Park
Jong Kyu
JK
Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Bucheon, Korea.
Lee
Moon Sung
MS
Ko
Bong Min
BM
Kim
Hyung Ki
HK
Kim
Young Jee
YJ
Choi
Hyun Jong
HJ
Hong
Su Jin
SJ
Ryu
Chang Beom
CB
Moon
Jong Ho
JH
Kim
Jin Oh
JO
Cho
Joo Young
JY
Lee
Joon Seong
JS
D000230:Adenocarcinoma / Q000150:complications* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D002277:Carcinoma / Q000150:complications / Q000556:secondary; D002858:Chromium Alloys; D020099:Coated Materials, Biocompatible; D003035:Cobalt; D003108:Colonic Diseases / Q000209:etiology / Q000601:surgery*; D003110:Colonic Neoplasms / Q000150:complications* / Q000556:secondary; D003113:Colonoscopy; D004867:Equipment Design; D005260:Female; D005471:Fluoroscopy; D005548:Foreign-Body Migration / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000473:pathology; D015641:Radiography, Interventional; D012002:Rectal Diseases / Q000209:etiology / Q000601:surgery*; D015607:Stents / Q000145:classification; D013274:Stomach Neoplasms / Q000473:pathology; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology
D000497:Alloys; D002858:Chromium Alloys; D020099:Coated Materials, Biocompatible; C112499:phynox; C013616:nitinol; D003035:Cobalt